• 1
    Dong XP, Stubenrauch F, Beyer-Finkler E, et al. 1994. Prevalence of deletions of YY1-binding sites in episomal HPV16 DNA from cervical cancers. Int J Cancer 1994;58: 8038.
  • 2
    Villa LL, Sichero L, Rahal P, et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000;81: 295968.
  • 3
    Chan SY, Ho L, Ong CK, et al. Molecular variants of human papillomavirus type 16 from 4 continents suggest ancient pandemic spread of the virus and its coevolution with humankind. J Virol 1992;66: 205766.
  • 4
    Yamada T, Manos MM, Peto J, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 1997;71: 246372.
  • 5
    Conrad Stöppler M, Ching K, Stöppler H, et al. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 1996;70: 698793.
  • 6
    Giannoudis A, Herrington CS. Human papillomavirus variants and squamous neoplasia of the cervix. J Pathol 2001;193: 295302.
  • 7
    Casas L, Galvan SC, Ordoñez RM, et al. Asian-American variants of human papillomavirus type 16 have extensive mutations in the E2 gene and are highly amplified in cervical carcinomas. Int J Cancer 1999;83: 44955.
  • 8
    Veress G, Szarka K, Dong XP, et al. Functional significance of sequence variation in the E2 gene and the long control region of human papillomavirus type 16. J Gen Virol 1999;80: 103543.
  • 9
    Cullen AP, Reid R, Campion M, et al. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 1991;65: 60612.
  • 10
    Yee C, Krishnan-Hewlett Z, Baker CC, et al. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol 1985;119: 3616.
  • 11
    May M, Dong XP, Beyer-Finkler E, et al. 1994. The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1. EMBO J 1994;13: 14606.
  • 12
    Wheeler CM, Yamada T, Hildesheim A, et al. Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. J Clin Microbiol 1997;35: 119.
  • 13
    D as BC, Sharma JK, Gopalakrishna V, et al. Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions. J Gen Virol 1992;73: 232736.
  • 14
    Rose BR, Thompson CH, Chantrill LA, et al. Prevalence and distribution of human papillomavirus type-16 DNA in pelvic lymph nodes of patients with cervical cancer and in women with no history of cervical abnormality. Int J Cancer 1992;53: 14.
  • 15
    Lis JT. Size fractionation of DNA fragments by polyethylene glycol induced precipitation. Meth Enzymol 1980;65: 34753.
  • 16
    Seedorf K, Krämmer G, Dürst M, et al. Human papillomavirus type 16 DNA sequence. Virology 1985;145: 1815.
  • 17
    Meyers G, Delius H, Icenogel J, et al. Human papillomaviruses. Los Alamos: Los Alamos National Laboratory, 1995. III 4757.
  • 18
    Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982;157: 10532.
  • 19
    Jameson BA, Wolf H. The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci 1988;4: 1816.
  • 20
    Law CL, Merianos A, Grace J, et al. Clinical and virological associations between external anogenital warts and cervical infection in an STD clinic population. Int J STD AIDS 1991;2: 306.
  • 21
    Stephen AL, Thompson CH, Tattersall MH, et al. 2000. Analysis of mutations in the URR and E6/E7 oncogenes of HPV16 cervical cancer isolates from central China. Int J Cancer 2000;86: 695701.
  • 22
    Watts K, Thompson CH, Cossart YE, et al. 2001. Variable oncogene promoter activity of human papillomavirus type 16 cervical cancer isolates from Australia. J Clin Microbiol 2001;39: 200914.
  • 23
    Gao L, Chain B, Sinclair C, et al. Immune responses to human papillomavirus type 16 E6 gene in a live vaccinia vector. J Gen Virol 1994;75: 15764.
  • 24
    Kadish AS, Ho GYF, Burk RD, et al. 1997. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: Outcome of HPV infection and associated neoplasia. J Natl Cancer Inst 1997;89: 12581293.
  • 25
    Nindl I, Rindfleisch K, Lotz B, et al. 1999. Uniform distribution of HPV16 E6 and E7 variants in patients with normal histology, cervical intraepithelial neoplasia and cervical cancer. Int J Cancer 1999;82: 2037.
  • 26
    Zhebe I, Wilander E, Delius H, et al. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma then the prototype. Cancer Res 1998;58: 82933.
  • 27
    Zhebe I, Voglino G, Delius H, et al. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 1998;352: 14412.
  • 28
    Romanczuk H, Howley PM. Disruption of either the E1 or E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Nat Acad Sci USA 1992;89: 315963.
  • 29
    Sakai H, Yasugi T, Benson JD, et al. Targeted mutagenesis of the human papillomavirus type 16 E2 transactivation domain reveals separable transcriptional activation and DNA replication functions. J Virol 1996;70: 160211.
  • 30
    Kammer C, Warthorst U, Torrez-Martinez N, et al. Sequence analysis of the long control region of human papillomavirus type 16 variants and functional consequences for P97 promoter activity. J Gen Virol 2000;81: 19751981.
  • 31
    Kalantari M, Karlsen F, Kristensen G, et al. 1998. Disruption of the E1 and E2 reading frames of HPV16 in cervical carcinoma is associated with poor prognosis. Int J Gynecol Pathol 1998;17: 14653.
  • 32
    Eriksson A, Herron JR, Yamada T, et al. Human papillomavirus type 16 variant lineages characterized by nucleotide sequence analysis of the E5 coding segment and E2 hinge region. J Gen Virol 1999;80: 595600.